Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT) - Archive ouverte HAL Access content directly
Journal Articles Annals of Oncology Year : 2016

Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT)

(1) , (2) , (3) , (4) , (5) , (6) , (7, 8) , (9) , (10) , (11) , (12) , (13) , (14) , (15) , (16) , (17) , (17) , (17) , (17) , (17)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17

Abstract

.
Fichier principal
Vignette du fichier
AnnOncol2016Eq2.pdf (43.09 Ko) Télécharger le fichier
Origin : Files produced by the author(s)

Dates and versions

inserm-01407384 , version 1 (02-12-2016)

Identifiers

Cite

P. Saiag, R. Gutzmer, P. A. Ascierto, M. Maio, J.-J. Grob, et al.. Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT). Annals of Oncology, 2016, 27, pp.1947 - 1953. ⟨10.1093/annonc/mdw291⟩. ⟨inserm-01407384⟩
66 View
105 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More